News

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday.
In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.
The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...
This discovery could make treatment for an eye disease affecting millions with diabetes more accessible and affordable.
The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...
The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to HIV-prevention infrastructure in the U.S.